Royal Purple announced a new three-tier lineup of synthetic motor oils—High Performance, Ultimate High Performance, and Extreme Performance Racing—designed to meet the needs of daily drivers to race enthusiasts. The lineup simplifies product choice while enhancing engine protection with proprietary Synerlec® additive technology. The oils will be available in retail stores starting January 2027, with the official unveiling at AAPEX 2026. This launch aims to provide clear options for consumers seeking reliable and advanced lubrication solutions for various vehicle demands.
Royal Purple's new motor oil lineup is the subject, with Pluang's Consumer Cyclical sector data as context. As of Nov 02, 2026 19:11 WIB, out of 134 priced US stocks in this sector, 81 rose and 28 fell. Notable movers include RIVN at USD 12.58 with a 3.45% increase, BABA at USD 101.31 up 3.41%, and MAR at USD 410.75 rising 2.87%.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
